Amid market volatility, one investor outlines a strategic pivot towards Brookfield Renewable, Hormel Foods, and Clorox, betting on their resilient dividends and growth potential.
The Pan American Health Organization urges heightened surveillance and vaccination efforts as confirmed measles cases surge dramatically across the region, reversing years of progress.
As reproductive rights face escalating legal threats, personal finance experts are advising clients to prioritize dedicated savings for abortion access—a stark reflection of America's shifting healthcare landscape.
Novo Nordisk reports unprecedented early uptake of its oral Wegovy, with weekly prescriptions hitting 50,000 within weeks of its U.S. debut. The pill's lower price and convenience are broadening access to GLP-1 treatments amid a rapidly evolving market.
As Bitcoin struggles below $76,000, industry titans Mike Novogratz and Michael Burry offer starkly contrasting outlooks. This analysis delves into their arguments, the impact of ETFs, and a broader macroeconomic theory that could redefine Bitcoin's role between 'inside' and 'outside' money.
A coalition of major investors has filed resolutions challenging BP's pivot back toward oil and gas, demanding greater transparency on capital allocation and how the strategy aligns with earlier climate pledges ahead of the annual meeting.
NGL Energy Partners (NGL) reported robust quarterly results, featuring record water disposal volumes and significant adjusted EBITDA growth. The partnership's units have surged over 20% in the past month, prompting investors to question if the stock still holds value after its impressive run.
A comprehensive new ranking places Atlanta as the nation's second-best metro for STEM professionals, highlighting its robust job market, high wages, and quality of life, while identifying the top and bottom cities for science and tech careers.
Axsome Therapeutics' preliminary 2025 results reveal blockbuster-level sales for its depression drug Auvelity, while investor focus intensifies on its potential FDA label expansion for Alzheimer's disease agitation—a move that could redefine the company's valuation and pipeline prospects.
A new analysis reveals the stark income gap facing working parents in the Washington, D.C. area, where the cost of childcare far outpaces typical household earnings, mirroring a national crisis.
For retirees, neglecting to rebalance an investment portfolio is no longer a minor oversight—it's a critical risk that can amplify losses, deplete reserves, and permanently alter a retirement's trajectory. Behavioral biases and market momentum often conspire to create a dangerous imbalance between stocks and bonds, leaving savers exposed just when protection matters most.
A Democratic-led push to study replacing California's gas tax with a per-mile road usage charge has ignited fierce Republican opposition, framing the debate as a critical test for infrastructure funding as fuel tax revenues decline nationwide.
A sharp decline in legal sports wagers in Illinois, coinciding with recent tax increases, points to a growing shift of bettors toward untaxed and unregulated offshore sites and local bookmakers, according to industry analysis.
A new WalletHub analysis of 182 U.S. cities places Detroit among the lowest for household budgeting skills, highlighting stark contrasts in spending, credit, and savings behaviors across the nation.
In a major settlement with the Federal Trade Commission, Cigna's pharmacy benefit manager, Express Scripts, has agreed to overhaul its drug pricing practices, particularly for insulin, a move regulators estimate could save patients billions over the next decade.
Market volatility can test any investor's resolve. We analyze six monthly dividend ETFs designed to provide income and potential stability when markets turn south, examining their strategies, holdings, and historical performance.
As Qualcomm prepares to report Q1 FY2026 earnings, the chipmaker faces a pivotal moment. Mounting competition from Apple's in-house modems, a slowing handset market, and regulatory pressures in China have investors on edge, setting the stage for a report that could redefine the stock's trajectory.
Japanese pharmaceutical giant Shionogi reports robust nine-month results, driving a significant share price surge. As the stock trades above some analyst targets yet below intrinsic value estimates, investors are weighing whether the momentum has run its course or if there's still room to grow.
Devon Energy's stock presents a conundrum for investors. While recent performance has been strong, a deep dive into its discounted cash flow and P/E ratio suggests the shares may be trading at a significant discount to their intrinsic value. We examine the numbers and what they could mean for the oil and gas producer's future.
ATI's shares have more than doubled over the past 12 months, fueled by its strategic position in capital goods and aerospace. As the stock trades near $128, analysts are divided on whether the current valuation still offers room for growth or signals a pause.
